摘要就促进骨形成药物、钙剂及维生素D、运动锻炼及外科手术治疗骨质疏松症的进展作一综述。The advances in bone formation-accelerating drugs, calcium and vitamin D, exercises and surgery treating osteoprosis are reviewed.
2Nishio E, Tomiyama K, Nakata H, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell differentiation incultured adipogenic cells(3-T3-L1) [J]. Eur J Pharma,1996, 301:203-206.
3Mundy G, Garrert R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins[J ]. Science, 1999, 286:1946-1949.
4Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxy-methylglutaryl-coenzyme. A reductase and risk of fracture among older women[J ]. Lancet, 2000, 355 : 2185-2188.
5Wang P, Solomon DH, Hogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients[J ]. JAMA, 2000, 283:3211-3216.
6Chan MH, Mak TW, Chiu RW, et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia[J] .J Clin Endocrinol Metab, 2001, 86:4556-4559.
7Riggs BL, Khosla S, Melton Ⅲ LJ. Sex steroids and the construction and conservation of the adult skeleton[J]. Endocrine Reviews, 2002,23: 279-302.
8Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegrin in postmenopausal women [ J ] J Bone Miner Res,2001,16 : 348-360.
9Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases[J ]. J Clin Endocrinol Metab, 2000, 85:2355-2363.
10Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclar factor-kB ligand and osteoprotegerin. Potential implications for the pathogenesis and treatment of malignant bone diseases [ J ]. Cancer,2001, 92: 460-470.
二级参考文献13
1Friedman J M,Halaas J L.Leptin and the regulation of body weight in mammals[J].Nature,1997,395:763-770.
2Rexford S A, Jeffery, S F. Adipose tissue as an endocrine organ[J]. J Endocrinol Metab, 2000,11:327-332.
3Sethi J, Hotamisligil G S. The role of TNF-α in adipocyte metabolism[J]. Semin Cell Dev Biol, 1999,10:19-29.
4Mohamed A V, Goodrick S, Rawesh A,et al. Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-α,in vivo [J]. J Clin Endocrinol Metab,1997,82:4196-4200.
5Jean P B, Claude J, Eric B, et al. Elevated level of interleukin 6 are reduced in serum after weight loss[J]. J Clin Endocrinol Metab,2000,85:3338-3342.
6Bastard P B, Jardel C, Delattre J, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects[J].Circulation,1999,99:2221-2222.
7Hallenx C M, Delerck P J,Tran S L,et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines[J]. J Clin Endocrinol Metab,1999,84:4097-4105.
8Cianflone K, Maslowska M, Sniderman A D, et al.Acylation stimulating protein(ASP) an adipocyte autocrine new directions[J]. Semin Cell Dev Biol,1999,10:31-41.
9Hu E, Liang P, Spieglman B M, et al. Adipo Q is a novel adipose-specific gene dysregulated in obesity [J]. J Biol Chem,1996,271:10697-10703.
7Angulo P,Therneau TM, Jorgensen A, et al. Bone disease inpatients with primary sclerosing cholangitis: prevalence, severity and prediction of progression [ J ]. J Hepatol, 1998,29 (5) :729-735.
8Genant HK, Cooper C, Reid I, et al. Interim report and reeommendas of the world health organization task-force for osteoporosis [ J ]. Osteoporosis Int,1999,10(4) :259-264.
9Menon KV, Angulo P,WestonS,et al. Bone disease in primary biliary cirrhosis:independent indicators and rate of progression [ J ]. J Hepatol,2001,35 (3) :316-323.
10Pereira SP, Bray GP, Pitt PI, et al. Non-invasive assessment of bone density inprimary biliary cirrhosis [ J ]. Eur J Gastroenterol Hepatol, 1999,11 (3) :323-328.
